HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reversal of experimental pulmonary hypertension by PDGF inhibition.

Abstract
Progression of pulmonary hypertension is associated with increased proliferation and migration of pulmonary vascular smooth muscle cells. PDGF is a potent mitogen and involved in this process. We now report that the PDGF receptor antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 2 animal models of pulmonary hypertension. In rats with monocrotaline-induced pulmonary hypertension, therapy with daily administration of STI571 was started 28 days after induction of the disease. A 2-week treatment resulted in 100% survival, compared with only 50% in sham-treated rats. The changes in RV pressure, measured continuously by telemetry, and right heart hypertrophy were reversed to near-normal levels. STI571 prevented phosphorylation of the PDGF receptor and suppressed activation of downstream signaling pathways. Similar results were obtained in chronically hypoxic mice, which were treated with STI571 after full establishment of pulmonary hypertension. Moreover, expression of the PDGF receptor was found to be significantly increased in lung tissue from pulmonary arterial hypertension patients compared with healthy donor lung tissue. We conclude that STI571 reverses vascular remodeling and cor pulmonale in severe experimental pulmonary hypertension regardless of the initiating stimulus. This regimen offers a unique novel approach for antire-modeling therapy in progressed pulmonary hypertension.
AuthorsRalph Theo Schermuly, Eva Dony, Hossein Ardeschir Ghofrani, Soni Pullamsetti, Rajkumar Savai, Markus Roth, Akylbek Sydykov, Ying Ju Lai, Norbert Weissmann, Werner Seeger, Friedrich Grimminger
JournalThe Journal of clinical investigation (J Clin Invest) Vol. 115 Issue 10 Pg. 2811-21 (Oct 2005) ISSN: 0021-9738 [Print] United States
PMID16200212 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzamides
  • Piperazines
  • Platelet-Derived Growth Factor
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Receptors, Platelet-Derived Growth Factor
Topics
  • Animals
  • Benzamides
  • Blood Pressure (drug effects)
  • Disease Models, Animal
  • Heart Ventricles (metabolism, pathology)
  • Humans
  • Hypertension, Pulmonary (drug therapy, pathology, physiopathology)
  • Imatinib Mesylate
  • Lung (blood supply, metabolism, pathology)
  • Male
  • Mice
  • Piperazines (administration & dosage)
  • Platelet-Derived Growth Factor (metabolism)
  • Protein Kinase Inhibitors (administration & dosage)
  • Pulmonary Artery (metabolism, pathology)
  • Pyrimidines (administration & dosage)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Platelet-Derived Growth Factor (antagonists & inhibitors, metabolism)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: